183 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast PeerView Press

    • Science
    • 3.8, 16 Ratings

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Richard S. Finn, MD - Patient Stories From the HCC CaseBook: Expert Guidance on Optimizing Outcomes and Care With Newly Available and Emerging Therapies

    Richard S. Finn, MD - Patient Stories From the HCC CaseBook: Expert Guidance on Optimizing Outcomes and Care With Newly Available and Emerging Therapies

    Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don’t miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs.

    • 1 hr 5 min
    David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

    David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents

    Go online to PeerView.com/JQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses practical strategies for choosing treatments based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric cancer. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

    • 1 hr 6 min
    Harry P. Erba, MD, PhD - Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations

    Harry P. Erba, MD, PhD - Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations

    Go online to PeerView.com/JTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of hematology-oncology experts use the evidence that has revolutionized modern acute myeloid leukemia (AML) treatment as a starting point for exploring how the data have influenced clinical decision-making in varied AML populations. Themes to be explored in the tumor board sessions include the judicious use of newer cytotoxic formulations, targeted agents, and novel epigenetic strategies for older patients with AML or those with high-risk or mutation-defined disease. Upon completion of this activity, participants should be better able to: Identify patient- and disease-related features, including age, cytogenetics, and mutational status, that may influence prognosis and treatment decisions for AML, Summarize efficacy and safety data surrounding novel agent classes in different AML settings, including as induction/consolidation therapy, maintenance therapy, and salvage therapy, Recommend novel therapies, including newer cytotoxic formulations, epigenetic agents, antibodies, and targeted agent classes, for patients with AML after considering relevant prognostic and other baseline features, Develop a management protocol for treatment-related adverse events associated with novel therapies used to treat AML.

    • 1 hr 7 min
    "Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?"

    "Robert D. McBane, II, MD - Taking a New Look at Cancer-Associated Venous Thromboembolism: How Is Emerging Evidence Influencing Guidelines & Practice?"

    Go online to PeerView.com/TGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in venous thromboembolism (VTE) reviews the latest clinical science and guidelines pertaining to cancer-associated VTE prophylaxis and treatment. This video-based program also focuses on strategies to help learners prepare for the practical integration of direct oral anticoagulants (DOACs) in cancer-associated VTE and illustrates how this development can lead to clinical improvements in the prevention and management of VTE in the cancer setting. Upon completion of this activity, participants will be able to: Use established clinical tools to assess the risk for VTE in patients preparing to receive anticancer therapy, Summarize current evidence and guidelines on VTE treatment and prophylaxis including the use of direct oral anticoagulation in patients with cancer, Apply updated evidence on the use of DOACs as initial VTE therapy and/or thromboprophylaxis in the cancer setting.

    • 33 min
    Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC

    Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC

    Go online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology, Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations, Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials.

    • 1 hr
    Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer

    Joyce O’Shaughnessy, MD - Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer

    Go online to PeerView.com/BKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, breast cancer experts discuss the latest evidence on the use of CDK4 and 6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer. An essential overview of mechanisms of action of this therapeutic class, similarities/differences among the agents, and latest approvals/indications is provided, along with a summary and analysis of the current state of the science. Practicalities of clinical integration of the CDK4 and 6 inhibitors are also explored, with a focus on navigating the current treatment landscape and making individualized clinical decisions. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanism of action, and characteristics (including similarities/differences) of the CDK4 and 6 inhibitors in breast cancer, Analyze the latest efficacy (including OS), safety, and other key data from clinical trials assessing CDK4 and 6 inhibitors in breast cancer, and relevant implications for clinical practice, Discuss the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive biomarkers that could be used to guide selection of patients who would benefit from CDK4 and 6 inhibitors, Incorporate CDK4 and 6 inhibitors alone or in combination into treatment plans for appropriate patients with hormone receptor–positive, HER2-negative advanced breast cancer according to relevant evidence, clinical guidelines, predictive factors, and patient needs and preferences, Manage treatment-related toxicities in patients with breast cancer undergoing treatment with CDK4 and 6 inhibitors to maintain optimal adherence and promote favorable outcomes.

    • 1 hr 17 min

Customer Reviews

3.8 out of 5
16 Ratings

16 Ratings

Dr.Job ,

AmaZing Material for internists

I cannot describe how nice and neat it was to listen to this material.

Basim Ayoub, MD

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press